Total synthesis of Zoanthamine

佐安他明的全合成

• 批准号: 7002208
• 负责人: Fatima R Rivas
• 金额: $ 2.79万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN DIEGO
• 依托单位国家: 美国
• 财政年份: 2003
• 资助国家: 美国
• 起止时间: 2003-01-01 至 2006-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7002208
• 关键词: Total; synthesis; Zoanthamine

DESCRIPTION (provided by applicant): Our goal is to develop a feasible synthetic procedure that can yield Zoanthamine and other members of this alkaloid family such as norzoanthamine in a concise manner. Most of these alkaloids possess highly functionalized trans-decalone and heterocyclic aminal ring system along with at least three quaternary chiral centers (C-9, C-12, C-22 for zoanthamine). Zoanthamine and its relatives were found to inhibit phorbol myristate acetate induced inflammation in a model system. Norzoanthamine was found to inhibit the growth of P388 murine leukemia cell cultures. In addition, norzoanthamine inhibits IL-6 production. Recently, it has been reported that zoanthamine-type alkaloids suppress the decrease in bone weight. The construction of the core of zoanthamine will lead us to hopefully develop a library of its analogs to further study their potential as candidates for an osteoporotic drug and/or an anti-inflammatory drug.

描述（由申请人提供）：我们的目标是开发一种可行的合成方法，可以以简洁的方式产生Zoanthamine和该生物碱家族的其他成员，如norzoanthamine。这些生物碱大多数具有高度官能化的反式十烷酮和杂环缩醛胺环系统，沿着有至少三个季手性中心（zoanthamine为C-9，C-12，C-22）。Zoanthamine及其相关物被发现在模型系统中抑制佛波醇肉豆蔻酸酯乙酸酯诱导的炎症。去甲虫胺被发现抑制P388小鼠白血病细胞培养物的生长。此外，norzoanthamine抑制IL-6的产生。 最近，据报道，Zoanthamine型生物碱抑制骨重量的减少。 Zoanthamine核心的构建将使我们有希望开发其类似物的库，以进一步研究其作为抗肿瘤药物和/或抗炎药物候选物的潜力。